Open Access
Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases
GAKU YAMAMICHI, TAIGO KATO, AKIHIRO YOSHIMURA, MASARU TANI, YUKI HORIBE, YUTONG LIU, NESRINE SASSI, YOHEI OKUDA, TOSHIKI OKA, TOSHIHIRO UEMURA, AKINARU YAMAMOTO, YU ISHIZUYA, TAKUJI HAYASHI, YOSHIYUKI YAMAMOTO, KOJI HATANO, ATSUNARI KAWASHIMA, TETSUYA TAKAO, KENSAKU NISHIMURA, SHINGO TAKADA, MASAO TSUJIHATA and NORIO NONOMURA
Anticancer Research February 2025, 45 (2) 639-650; DOI: https://doi.org/10.21873/anticanres.17451